JTE-451

Akros Pharma Inc. · Phase 1 active Small molecule

JTE-451 is a small molecule in development by Akros Pharma Inc. for moderate to severe plaque psoriasis. It has completed Phase 1 and Phase 2 trials, showing promising efficacy and safety profiles. The drug targets a novel mechanism, potentially offering a new treatment option for patients with this chronic condition.

At a glance

Generic name	JTE-451
Sponsor	Akros Pharma Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

JTE-451 CI brief — competitive landscape report
JTE-451 updates RSS · CI watch RSS
Akros Pharma Inc. portfolio CI